- Home
- MBC vs GLPG Comparison
MBC vs GLPG Comparison
Compare MBC & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MBC
- GLPG
- Stock Information
- Founded
- MBC 1954
- GLPG 1999
- Country
- MBC United States
- GLPG Belgium
- Employees
- MBC N/A
- GLPG N/A
- Industry
- MBC Agricultural Chemicals
- GLPG Biotechnology: Pharmaceutical Preparations
- Sector
- MBC Industrials
- GLPG Health Care
- Exchange
- MBC Nasdaq
- GLPG Nasdaq
- Market Cap
- MBC 1.5B
- GLPG 1.8B
- IPO Year
- MBC N/A
- GLPG 2005
- Fundamental
- Price
- MBC $11.11
- GLPG $26.86
- Analyst Decision
- MBC Strong Buy
- GLPG Sell
- Analyst Count
- MBC 1
- GLPG 4
- Target Price
- MBC $15.00
- GLPG $25.33
- AVG Volume (30 Days)
- MBC 1.2M
- GLPG 489.3K
- Earning Date
- MBC 05-06-2025
- GLPG 04-23-2025
- Dividend Yield
- MBC N/A
- GLPG N/A
- EPS Growth
- MBC N/A
- GLPG N/A
- EPS
- MBC 0.77
- GLPG N/A
- Revenue
- MBC $2,722,600,000.00
- GLPG $311,493,731.00
- Revenue This Year
- MBC $2.24
- GLPG $0.78
- Revenue Next Year
- MBC $3.69
- GLPG N/A
- P/E Ratio
- MBC $14.39
- GLPG N/A
- Revenue Growth
- MBC 1.30
- GLPG 18.32
- 52 Week Low
- MBC $10.07
- GLPG $22.36
- 52 Week High
- MBC $20.67
- GLPG $31.23
- Technical
- Relative Strength Index (RSI)
- MBC 45.04
- GLPG 58.65
- Support Level
- MBC $9.78
- GLPG $24.74
- Resistance Level
- MBC $11.45
- GLPG $27.81
- Average True Range (ATR)
- MBC 0.50
- GLPG 0.78
- MACD
- MBC 0.00
- GLPG 0.00
- Stochastic Oscillator
- MBC 48.36
- GLPG 69.06
About MBC MasterBrand Inc.
MasterBrand Inc operates as a residential cabinet manufacturer in North America. It offers a comprehensive portfolio of residential cabinetry products for the kitchen, bathroom, and other parts of the home. The firm sells its products throughout the United States and Canada through three primary channels: dealers, retailers and builders.
About GLPG Galapagos NV
Galapagos NV is a fully integrated biotechnology company focused on discovering, developing, and commercializing medicines. The company is committed to improving patients' lives world-wide by targeting diseases with high unmet needs. Its R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Its portfolio comprises discovery through to commercialized programs in immunology, oncology, and other indications. Its first medicine for rheumatoid arthritis and ulcerative colitis is available in Europe and Japan. It derives maximum revenue from United States of America.